Effect of terazosin on urine storage and voiding in the aging male with prostatism.
Patients in a private practice, evaluated for prostatism due to benign prostatic hypertrophy were offered the options of medical treatment with the alpha blocker terazosin, surgical treatment, or continued observation. Nineteen men accepted terazosin treatment and are the subjects of the present series. They were treated over a mean period of 8 months, the longest treatment lasting over 22 months. Dosage was started at 1 mg/d and increased as tolerated to 2, 5, and 10 mg/d over the test period. Extensive testing including invasive urodynamics, multiple voiding diaries, and symptoms scores at each dosage level was carried out. We found that flow rates increased moderately from baseline in a dose dependent fashion. At the 10 mg/d dosage some patients achieved flow rates in the low normal range. Patients on treatment documented a decrease in the number of voidings per day, a decrease in nocturia, an increase in bladder capacity and the volume of each voiding. On the other hand, patients frequently did not appreciate changes in their voiding patterns, as reflected in their responses to the symptom questionnaires. We could not demonstrate significant changes in bladder pressures on cystometry either during filling or voiding. Our data suggested that terazosin may well have a direct effect on the fundus of the aging bladder to increase capacity, and, through the well-known relationship between voided volume and flow rate, increase urinary flow rate.
Gleason
D M
DM
Urodynamics Laboratory, Tucson Medical Center, Arizona 85712.
Bottaccini
M R
MR
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D011795:Surveys and Questionnaires; D013997:Time Factors; D001743:Urinary Bladder / Q000187:drug effects / Q000503:physiopathology*; D014554:Urination / Q000187:drug effects*
D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D011224:Prazosin